Literature DB >> 23041678

Fecal microbiota transplantation: past, present and future.

Olga C Aroniadis1, Lawrence J Brandt.   

Abstract

PURPOSE OF REVIEW: Fecal microbiota transplantation (FMT) re-establishes a balanced intestinal flora with resultant cure of recurrent Clostridium difficile infection (RCDI). FMT has also been used to treat other gastrointestinal (GI) diseases including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation and a variety of non-GI disorders. The purpose of this review is to discuss the intestinal microbiota and FMT treatment of GI and non-GI diseases. RECENT
FINDINGS: It is known that an imbalanced intestinal microbiota predisposes to CDI, IBD and IBS. The complex role of intestinal microbiota to maintain health, however, is a newer concept that is being increasingly studied. The microbiome plays an important role in cellular immunity and energy metabolism and has been implicated in the pathogenesis of non-GI autoimmune diseases, chronic fatigue syndrome, obesity and even some neuropsychiatric disorders.
SUMMARY: FMT is a highly effective cure for RCDI, but increased knowledge of the intestinal microbiota in health maintenance, as well as controlled trials of FMT in a wide range of disorders are needed before FMT can be accepted and applied clinically.

Entities:  

Mesh:

Year:  2013        PMID: 23041678     DOI: 10.1097/MOG.0b013e32835a4b3e

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  121 in total

1.  The Brain-Gut-Microbiome Axis: What Role Does It Play in Autism Spectrum Disorder?

Authors:  Ruth Ann Luna; Tor C Savidge; Kent C Williams
Journal:  Curr Dev Disord Rep       Date:  2016-02-26

Review 2.  The microbiome: stress, health and disease.

Authors:  Rachel D Moloney; Lieve Desbonnet; Gerard Clarke; Timothy G Dinan; John F Cryan
Journal:  Mamm Genome       Date:  2013-11-27       Impact factor: 2.957

Review 3.  Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation.

Authors:  Anastasia I Petra; Smaro Panagiotidou; Erifili Hatziagelaki; Julia M Stewart; Pio Conti; Theoharis C Theoharides
Journal:  Clin Ther       Date:  2015-05-01       Impact factor: 3.393

Review 4.  The devil lies in the details: how variations in polysaccharide fine-structure impact the physiology and evolution of gut microbes.

Authors:  Eric C Martens; Amelia G Kelly; Alexandra S Tauzin; Harry Brumer
Journal:  J Mol Biol       Date:  2014-07-12       Impact factor: 5.469

Review 5.  Novel Indications for Fecal Microbial Transplantation: Update and Review of the Literature.

Authors:  Nathaniel Aviv Cohen; Nitsan Maharshak
Journal:  Dig Dis Sci       Date:  2017-03-17       Impact factor: 3.199

Review 6.  Gut microbiota in autism and mood disorders.

Authors:  Francesca Mangiola; Gianluca Ianiro; Francesco Franceschi; Stefano Fagiuoli; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 7.  Inflammatory bowel disease as a model for translating the microbiome.

Authors:  Curtis Huttenhower; Aleksandar D Kostic; Ramnik J Xavier
Journal:  Immunity       Date:  2014-06-19       Impact factor: 31.745

Review 8.  Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?

Authors:  Giovanni Cammarota; Gianluca Ianiro; Stefano Bibbò; Antonio Gasbarrini
Journal:  Intern Emerg Med       Date:  2014-03-25       Impact factor: 3.397

9.  Capsulized faecal microbiota transplantation ameliorates post-weaning diarrhoea by modulating the gut microbiota in piglets.

Authors:  Wenjie Tang; Daiwen Chen; Bing Yu; Jun He; Zhiqing Huang; Ping Zheng; Xiangbing Mao; Yuheng Luo; Junqiu Luo; Quyuan Wang; Huifen Wang; Jie Yu
Journal:  Vet Res       Date:  2020-04-16       Impact factor: 3.683

Review 10.  Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes.

Authors:  Altin Gjymishka; Roxana M Coman; Todd M Brusko; Sarah C Glover
Journal:  Immunotherapy       Date:  2013-12       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.